

Guy Jerusalem

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6627946/publications.pdf>

Version: 2024-02-01

76
papers

7,026
citations

136950

32
h-index

66911

78
g-index

81
all docs

81
docs citations

81
times ranked

9692
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Hypnosis, Meditation, and Self-Induced Cognitive Trance to Improve Post-treatment Oncological Patientsâ€™ Quality of Life: Study Protocol. <i>Frontiers in Psychology</i> , 2022, 13, 807741. | 2.1 | 7 |
| 2 | Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant. <i>European Journal of Cancer</i> , 2022, 164, 39-51. | 2.8 | 8 |
| 3 | Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR ⁺ HER2 ⁻ Advanced Breast Cancer in the MONALEESA-3 Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 326-335. | 2.4 | 2 |
| 4 | Randomized, Controlled Trial of an Intervention Combining Self-Care and Self-Hypnosis on Fatigue, Sleep, and Emotional Distress in Posttreatment Cancer Patients: 1-Year Follow-Up. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2022, 70, 136-155. | 1.8 | 7 |
| 5 | Psycho-oncology interventions focusing on fatigue and sleep disturbances. <i>Current Opinion in Oncology</i> , 2022, 34, 270-278. | 2.4 | 3 |
| 6 | nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 181-190.e2. | 2.4 | 23 |
| 7 | Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor ⁺ positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512. | 7.0 | 5 |
| 8 | CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 283-298. | 2.4 | 39 |
| 9 | Unplanned hospitalizations in older patients with cancer: Occurrence and predictive factors. <i>Journal of Geriatric Oncology</i> , 2021, 12, 368-374. | 1.0 | 14 |
| 10 | Ribociclib plus fulvestrant in the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 93-106. | 2.4 | 9 |
| 11 | Metastatic colorectal cancer cells maintain the TGF β 2 program and use TGFBI to fuel angiogenesis. <i>Theranostics</i> , 2021, 11, 1626-1640. | 10.0 | 45 |
| 12 | A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8. | 5.0 | 15 |
| 13 | Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology. <i>JCO Global Oncology</i> , 2021, 7, 162-172. | 1.8 | 38 |
| 14 | Exploratory Controlled Study of the Impact of a Hypnosis-Based Intervention on the Coupleâ€™s Communication and Coping in the Context of Cancer. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2021, 69, 261-276. | 1.8 | 2 |
| 15 | Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458. | 3.7 | 17 |
| 16 | Optimal treatment in locally advanced cervical cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 657-671. | 2.4 | 23 |
| 17 | Immunity and Breast Cancer: Focus on Eosinophils. <i>Biomedicines</i> , 2021, 9, 1087. | 3.2 | 15 |
| 18 | Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421. | 3.7 | 12 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Neutropenia management in patients receiving myelosuppressive polychemotherapy for early breast cancer in Belgium: BRONS study results. <i>Acta Clinica Belgica</i> , 2020, 75, 128-135. | 1.2 | 3 |
| 20 | Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 514-524. | 27.0 | 482 |
| 21 | Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy. <i>Cancer Medicine</i> , 2020, 9, 8432-8443. | 2.8 | 4 |
| 22 | Cutaneous Breast Cancer Metastases Successfully Treated Using an Oxygen Flow Assisted Topical Administration of Methotrexate (OFAMTX). <i>Dermatology and Therapy</i> , 2020, 10, 855-861. | 3.0 | 1 |
| 23 | Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097. | 6.3 | 59 |
| 24 | Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. <i>Oncolimmunology</i> , 2020, 9, 1761176. | 4.6 | 22 |
| 25 | Impact of self-perception of aging on mortality of older patients in oncology. <i>Cancer Medicine</i> , 2020, 9, 2283-2289. | 2.8 | 7 |
| 26 | Effects of an intervention combining self-care and self-hypnosis on fatigue and associated symptoms in post-treatment cancer patients: A randomized-controlled trial. <i>Psycho-Oncology</i> , 2020, 29, 1165-1173. | 2.3 | 26 |
| 27 | Cardio-Oncology Services: rationale, organization, and implementation. <i>European Heart Journal</i> , 2019, 40, 1756-1763. | 2.2 | 195 |
| 28 | Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369. | 10.7 | 131 |
| 29 | HER2+ breast cancer treatment and cardiotoxicity: monitoring and management. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 237-250. | 2.5 | 84 |
| 30 | Health related quality of life in older patients with solid tumors and prognostic factors for decline. <i>Journal of Geriatric Oncology</i> , 2019, 10, 895-903. | 1.0 | 20 |
| 31 | Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 371-382. | 10.7 | 327 |
| 32 | Phase 1b Study of Trebananib Plus Paclitaxel and Trastuzumab in Patients With HER2-Positive Locally Recurrent or Metastatic Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, 47-57. | 2.4 | 8 |
| 33 | Expression of MT4-MMP, EGFR, and RB in Triple-Negative Breast Cancer Strongly Sensitizes Tumors to Erlotinib and Palbociclib Combination Therapy. <i>Clinical Cancer Research</i> , 2019, 25, 1838-1850. | 7.0 | 41 |
| 34 | First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study. <i>Breast</i> , 2018, 38, 144-149. | 2.2 | 10 |
| 35 | Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 671-686. | 2.5 | 564 |
| 36 | Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 127-138. | 10.7 | 91 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. <i>Journal of Clinical Oncology</i> , 2018, 36, 2465-2472. | 1.6 | 704 |
| 38 | Randomized controlled trial of an 8-week intervention combining self-care and hypnosis for post-treatment cancer patients: study protocol. <i>BMC Cancer</i> , 2018, 18, 1113. | 2.6 | 7 |
| 39 | Predictive and prognostic role of peripheral blood eosinophil count in triple-negative and hormone receptor-negative/HER2-positive breast cancer patients undergoing neoadjuvant treatment. <i>Oncotarget</i> , 2018, 9, 33719-33733. | 1.8 | 18 |
| 40 | Exercise and Education Program After Breast Cancer: Benefits on Quality of Life and Symptoms at 3, 6, 12, and 24 Months Follow-up. <i>Clinical Breast Cancer</i> , 2018, 18, e1189-e1204. | 2.4 | 15 |
| 41 | Natural Antisense Transcripts: Molecular Mechanisms and Implications in Breast Cancers. <i>International Journal of Molecular Sciences</i> , 2018, 19, 123. | 4.1 | 69 |
| 42 | Variations of circulating cardiac biomarkers during and after anthracycline-containing chemotherapy in breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 102. | 2.6 | 50 |
| 43 | Codon-specific translation reprogramming promotes resistance to targeted therapy. <i>Nature</i> , 2018, 558, 605-609. | 27.8 | 177 |
| 44 | MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. <i>British Journal of Cancer</i> , 2017, 116, 742-751. | 6.4 | 13 |
| 45 | Group interventions to reduce emotional distress and fatigue in breast cancer patients: a 9-month follow-up pragmatic trial. <i>British Journal of Cancer</i> , 2017, 117, 1442-1449. | 6.4 | 49 |
| 46 | Protocol update and preliminary results of EACVI/HFA Cardiac Oncology Toxicity (COT) Registry of the European Society of Cardiology. <i>ESC Heart Failure</i> , 2017, 4, 312-318. | 3.1 | 22 |
| 47 | Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700. | 10.7 | 451 |
| 48 | The link between self-perceptions of aging, cancer view and physical and mental health of older people with cancer: A cross-sectional study. <i>Journal of Geriatric Oncology</i> , 2017, 8, 64-68. | 1.0 | 19 |
| 49 | Transcriptome-wide analysis of natural antisense transcripts shows their potential role in breast cancer. <i>Scientific Reports</i> , 2017, 7, 17452. | 3.3 | 39 |
| 50 | Association between self-perception of aging, view of cancer and health of older patients in oncology: a one-year longitudinal study. <i>BMC Cancer</i> , 2017, 17, 614. | 2.6 | 18 |
| 51 | Multidisciplinary rehabilitation program after breast cancer: benefits on physical function, anthropometry and quality of life. <i>European Journal of Physical and Rehabilitation Medicine</i> , 2017, 53, 633-642. | 2.2 | 44 |
| 52 | Intérêt de l'hypnose en oncologie et dans la pratique de l'hépatogastro-entérologie. <i>HEGEL - HEpatogastroEntérologie Libérale</i> , 2017, N° 1, 101-102. | 0.0 | 3 |
| 53 | Triple-negative breast cancer: treatment challenges and solutions. <i>Breast Cancer: Targets and Therapy</i> , 2016, 8, 93. | 1.8 | 201 |
| 54 | Multidisciplinary management of breast cancer. <i>Archives of Public Health</i> , 2016, 74, 50. | 2.4 | 15 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Tissue Factor Induced by Epithelial-Mesenchymal Transition Triggers a Procoagulant State That Drives Metastasis of Circulating Tumor Cells. <i>Cancer Research</i> , 2016, 76, 4270-4282. | 0.9 | 81 |
| 56 | Safety, Efficacy, and Patient Acceptability of Everolimus in the Treatment of Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2016, 10, BCBCR.S12443. | 1.1 | 8 |
| 57 | Circulating microRNA-based screening tool for breast cancer. <i>Oncotarget</i> , 2016, 7, 5416-5428. | 1.8 | 66 |
| 58 | Ageism and its clinical impact in oncogeriatrics: state of knowledge and therapeutic leads. <i>Clinical Interventions in Aging</i> , 2015, 10, 117. | 2.9 | 49 |
| 59 | Patterns of resource utilization and cost for postmenopausal women with hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer in Europe. <i>BMC Cancer</i> , 2015, 15, 787. | 2.6 | 6 |
| 60 | Evaluation of BRCA1-related molecular features and microRNAs as prognostic factors for triple negative breast cancers. <i>BMC Cancer</i> , 2015, 15, 755. | 2.6 | 17 |
| 61 | Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. <i>Oncotarget</i> , 2015, 6, 10253-10266. | 1.8 | 130 |
| 62 | Asporin Is a Fibroblast-Derived TGF- β 1 Inhibitor and a Tumor Suppressor Associated with Good Prognosis in Breast Cancer. <i>PLoS Medicine</i> , 2015, 12, e1001871. | 8.4 | 97 |
| 63 | Mesenchymal Stem Cells Shed Amphiregulin at the Surface of Lung Carcinoma Cells in a Juxtacrine Manner. <i>Neoplasia</i> , 2015, 17, 552-563. | 5.3 | 12 |
| 64 | A new era of improving progression-free survival with dual blockade in postmenopausal HR+, HER2-advanced breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 94-104. | 7.7 | 22 |
| 65 | A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2015, 152, 95-117. | 2.5 | 27 |
| 66 | Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. <i>Breast</i> , 2015, 24, 182-190. | 2.2 | 44 |
| 67 | BRCA1 germline mutation and glioblastoma development: report of cases. <i>BMC Cancer</i> , 2015, 15, 181. | 2.6 | 22 |
| 68 | Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. <i>Journal of Cellular Physiology</i> , 2015, 230, 473-481. | 4.1 | 39 |
| 69 | EGFR Activation and Signaling in Cancer Cells Are Enhanced by the Membrane-Bound Metalloprotease MT4-MMP. <i>Cancer Research</i> , 2014, 74, 6758-6770. | 0.9 | 33 |
| 70 | Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer. <i>Current Medical Research and Opinion</i> , 2014, 30, 1007-1016. | 1.9 | 42 |
| 71 | Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial. <i>Journal of the National Cancer Institute</i> , 2014, 106, djt337-djt337. | 6.3 | 218 |
| 72 | Expert Consensus for Multimodality Imaging Evaluation of Adult Patients during and after Cancer Therapy: A Report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Journal of the American Society of Echocardiography</i> , 2014, 27, 911-939. | 2.8 | 1,051 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4594-4600. | 1.6 | 553 |
| 74 | Positron emission tomography imaging for lymphoma. <i>Current Opinion in Oncology</i> , 2005, 17, 441-445. | 2.4 | 23 |
| 75 | ¹⁸ F-FDG PET in children with lymphomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 31-38. | 6.4 | 109 |
| 76 | Evaluation of Therapy for Lymphoma. <i>Seminars in Nuclear Medicine</i> , 2005, 35, 186-196. | 4.6 | 98 |